Antisense Pharma with a new company strategy
Antisense Pharma GmbH, a biopharmaceutical company with its headquarters in Regensburg and Munich, is developing new innovative cancer therapies. These therapies based on Antisense technology are highly specific and aim to place the body’s own immune system in the position of fighting the tumor itself. This private company was founded in 1998 and has the renowned MIG AG as the main investor, in addition to their investors such as S-Refit and Bayern Kapital. The company announced its adapted development strategy, which has been fully supported by the main investors.
The updated development programme is associated with the new delivery of the clinical development programme of the active substance derived from trabedersen for the treatment of brain tumours (gliomas) and the rapid further development of the so-called “next generation” substance TGF-β-inhibitor-oligonucleotide. Unfortunately the initial analyses of the efficacy profile during the phase 3 study in patients with glioma demonstrated an unfavorable risk-benefit profile. Consequently the company has decided to not pursue the very promising development of trabedersen to date in these patients. On the other hand development work on patients with pancreatic carcinoma and malignant melanoma (skin cancer) is being pursued. The adapted company strategy demanded a reduction of the size of the organisation to better address the present demands of the company. The company has outsourced non-critical expertise and reduced the number of employees by half. Additionally the company strengthened several key positions of senior management.
For more information see: